Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Jordan Iannuzzi, Caitlin T Yeo, Vicky Parkins, Dean Ruether, Errol Stewart, Denise Chan, Janice Pasieka, Kirstie Lithgow
BACKGROUND: Neuroendocrine tumors (NET) are neoplasms that secrete peptides and neuroamines. For gastroenteropancreatic (GEP) NET, surgical resection represents the only curative option. Ten-year imaging surveillance programs are recommended due to long time-to-recurrence following resection. We performed retrospective chart review evaluating radiation exposure and practice patterns from surveillance of completely resected GEP NET. METHODS: We performed a retrospective cohort study of cases with well-differentiated GEP NET from January 2005 to July 2020...
January 19, 2024: Cancers
#22
JOURNAL ARTICLE
Nils Florian Trautwein, Clemens Hinterleitner, Lena Sophie Kiefer, Stephan Singer, Sven Mattern, Johannes Schwenck, Gerald Reischl, Bence Sipos, Ulrich M Lauer, Helmut Dittmann, Lars Zender, Christian la Fougère, Martina Hinterleitner
AIM/INTRODUCTION: Peptide receptor radionuclide therapy (PRRT) represents a cornerstone of treatment regimens for patients with low proliferative neuroendocrine tumors (NETs). However, in patients experiencing somatostatin receptor-positive NET with higher proliferation rates, a value and potential therapeutic benefit of PRRT as part of multimodal treatment approaches and potentially with addition of radiosensitizing agents has not yet been established. PATIENTS AND METHODS: In this study, 20 patients with histologically confirmed gastroenteropancreatic (GEP) NET with proliferation rates (Ki67) between 15% and 55% were treated either with PRRT only (n = 10) or with a combination therapy (n = 10) comprising PRRT and capecitabine/temozolomide (CAP/TEM) for at least 2 consecutive cycles...
January 23, 2024: Clinical Nuclear Medicine
#23
REVIEW
Bonita Bennett, Linda Gardner, Pamela Ryan
BACKGROUND: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a diverse family of cancers that occur within the gastrointestinal tract and pancreas. Peptide receptor radionuclide therapy (PRRT) via 177Lu-DOTATATE is a newer therapeutic option for certain patients with somatostatin receptor-positive GEP-NETs. OBJECTIVES: This review informs on how oncology nurses treating patients with GEP-NETs receiving PRRT using 177Lu-DOTATATE can facilitate care. METHODS: Guidance on the monitoring, management, and care of patients undergoing PRRT for GEP-NETs was developed based on published literature and the nursing experience of the authors...
January 18, 2024: Clinical Journal of Oncology Nursing
#24
JOURNAL ARTICLE
Zenghong Wu, Guochen Shang, Kun Zhang, Weijun Wang, Mengke Fan, Rong Lin
BACKGROUND: Over the last few decades, the annual global incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) has steadily increased. Because of the complex and inconsistent treatment of GEP-NETs, the prognosis of patients with GEP-NETs is still difficult to assess. The study aimed to construct and validate the nomograms included treatment data for prediction overall survival (OS) in GEP-NETs patients. METHODS: GEP-NETs patients determined from the Surveillance, Epidemiology, and End Results (SEER)-13 registry database (1992-2018) and with additional treatment data from the SEER-18 registry database (1975-2016)...
January 19, 2024: International Journal of Surgery
#25
JOURNAL ARTICLE
Jonathan R Strosberg, Taymeyah Al-Toubah, Ghassan El-Haddad, Diane Reidy Lagunes, Lisa Bodei
Most well-differentiated neuroendocrine tumors (NETs) express high levels of somatostatin receptors, particularly subtypes 2 and 5. Somatostatin analogs (SSAs) bind to somatostatin receptors and are used for palliation of hormonal syndromes and control of tumor growth. The long-acting SSAs octreotide long-acting release and lanreotide are commonly used in the first-line metastatic setting because of their tolerable side effect profile. Radiolabeled SSAs are used both for imaging and for treatment of NETs. 177 Lu-DOTATATE is a β-emitting radiolabeled SSA that has been proven to significantly improve progression-free survival among patients with progressive midgut NETs and is approved for treatment of metastatic gastroenteropancreatic NETs...
January 18, 2024: Journal of Nuclear Medicine
#26
JOURNAL ARTICLE
Suzann Duan, Travis W Sawyer, Brandon L Witten, Heyu Song, Tobias Else, Juanita L Merchant
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are heterogeneous malignancies that arise from complex cellular interactions within the tissue microenvironment. Here, we sought to decipher tumor-derived signals from the surrounding microenvironment by applying digital spatial profiling (DSP) to hormone-secreting and non-functional GEP-NETs. By combining this approach with in vitro studies of human-derived organoids, we demonstrated the convergence of cell autonomous immune and pro-inflammatory proteins that suggests their role in neuroendocrine differentiation and tumorigenesis...
January 17, 2024: Journal of Pathology
#27
REVIEW
Erik S Mittra, Rebecca K S Wong, Celeste Winters, Adam Brown, Shondra Murley, Hagen Kennecke
Radioligand therapy (RLT) is a targeted approach to treating cancer that has been shown to be safe and effective in a variety of disease states, including gastroenteropancreatic neuroendocrine tumors, lymphoma, and most recently, advanced prostate cancer. In the United States, patient access to this therapy is currently variable. Implementation of new RLT programs and expansion of existing programs are needed to broaden patient access to and standardize the delivery of RLT, especially as new therapies are introduced into clinical practice...
January 12, 2024: Cancer Medicine
#28
JOURNAL ARTICLE
Marianne Pavel, Harald Lahner, Dieter Hörsch, Anja Rinke, Timm Denecke, Arend Koch, Benjamin Regnault, Dorit Helbig, Philipp Hoffmanns, Markus Raderer
BACKGROUND: In advanced neuroendocrine tumors (NET), antiproliferative treatment options beyond somatostatin analogs remain limited. Temozolomide (TMZ) has shown efficacy in NET alone or combined with other drugs. MATERIALS AND METHODS: SONNET (NCT02231762) was an open, multicenter, prospective, phase II study to evaluate lanreotide autogel 120 mg (LAN) plus TMZ in patients with progressive advanced/metastatic grade 1/2 gastroenteropancreatic (GEP) NET or of unknown primary...
January 11, 2024: Oncologist
#29
JOURNAL ARTICLE
Alessia Garufi, Riccardo Pettinari, Laura Monteonofrio, Giulia Puliani, Ilaria Virdia, Marialuisa Appetecchia, Fabio Marchetti, Mara Cirone, Silvia Soddu, Gabriella D'Orazi
Gastroenteropancreatic neuroendocrine neoplasms (GEP‑NEN) are a group of rare tumors whose specific pathogenetic mechanisms of resistance to therapies have not been completely revealed yet. Chemotherapy is the main therapeutic approach in patients with GEP‑NEN, however, novel combination regimens and targeted therapy are continuously explored. In the present study, the anticancer effect of a novel Ruthenium (Ru)(II)‑Bisdemethoxycurcumin (Ru‑bdcurc) compound was evaluated in BON‑1 cell line, one of the few cell lines derived from GEP‑NEN, largely used in experimental research of this type of tumors...
February 2024: Oncology Reports
#30
REVIEW
Francesco Panzuto, Stefano Partelli, Davide Campana, Filippo de Braud, Francesca Spada, Mauro Cives, Salvatore Tafuto, Alexia Bertuzzi, Fabio Gelsomino, Francesca Bergamo, Stefano Marcucci, Laura Mastrangelo, Sara Massironi, Marialuisa Appetecchia, Angelina Filice, Giuseppe Badalamenti, Mirco Bartolomei, Vito Amoroso, Luca Landoni, Maria Grazia Rodriquenz, Monica Valente, Annamaria Colao, Andrea Isidori, Giuseppe Fanciulli, Roberto Bollina, Michele Ciola, Giovanni Butturini, Riccardo Marconcini, Emanuela Arvat, Saverio Cinieri, Rossana Berardi, Sergio Baldari, Ferdinando Riccardi, Chiara Spoto, Dario Giuffrida, Domenico Gattuso, Diego Ferone, Maria Rinzivillo, Emilio Bertani, Annibale Versari, Alessandro Zerbi, Giuseppe Lamberti, Eleonora Lauricella, Sara Pusceddu, Nicola Fazio, Elisabetta Dell'Unto, Marco Marini, Massimo Falconi
Neuroendocrine neoplasms (NENs) are rare tumors with diverse clinical behaviors. Large databases like the Surveillance, Epidemiology, and End Results (SEER) program and national NEN registries have provided significant epidemiological knowledge, but they have limitations given the recent advancements in NEN diagnostics and treatments. For instance, newer imaging techniques and therapies have revolutionized NEN management, rendering older data less representative. Additionally, crucial parameters, like the Ki67 index, are missing from many databases...
January 4, 2024: Endocrine
#31
JOURNAL ARTICLE
Catherine H Davis, Amanda M Laird, Steven K Libutti
Gastroenteropancreatic neuroendocrine tumors (NETs), also historically known as carcinoids, are tumors derived of hormone-secreting enteroendocrine cells. Carcinoids may be found in the esophagus, stomach, small intestine, appendix, colon, rectum, or pancreas. The biologic behavior of carcinoids differs based on their location, with gastric and appendiceal NETs among the least aggressive and small intestinal and pancreatic NETs among the most aggressive. Ultimately, however, biologic behavior is most heavily influenced by tumor grade...
2024: Proceedings of the Baylor University Medical Center
#32
JOURNAL ARTICLE
Weilong Lin, Zhitao Zhu, Yuping Shang
PURPOSE: Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC) in children is an exceptionally rare and aggressive form of cancer. We aimed to conduct a population-based cohort study to predict overall survival (OS) in pediatric patients with GEP-NEC. METHODS: The Surveillance, Epidemiology, and End Results (SEER) database was employed to identify all pediatric patients with GEP-NEC diagnosed between 2000 and 2019. To create survival curves based on various criteria, Kaplane-Meier estimations were utilized...
January 2, 2024: Journal of Cancer Research and Clinical Oncology
#33
JOURNAL ARTICLE
David L Chan, Aimee R Hayes, Ioannis Karfis, Alice Conner, Magdalena Mileva, Elizabeth Bernard, Geoffrey Schembri, Shaunak Navalkissoor, Gopinath Gnanasegaran, Nick Pavlakis, Clémentine Marin, Bruno Vanderlinden, Patrick Flamen, Paul Roach, Martyn E Caplin, Christos Toumpanakis, Dale L Bailey
[18 F]FDG PET/CT and [68 Ga]Ga-DOTATATE PET/CT are both used to predict tumor biology in neuroendocrine neoplasms. Although the presence of discordant ([18 F]FDG-avid/non-[68 Ga]Ga-DOTATATE-avid) disease predicts poor prognosis, the significance of the volume of such discordant disease remains undetermined. The aim of this study is to investigate discordant tumor volume as a potential biomarker in patients with advanced gastroenteropancreatic neuroendocrine neoplasms (GEPNENs). Methods: A multicenter retrospective study in patients with advanced GEPNENs and paired [18 F]FDG and [68 Ga]Ga-DOTATATE PET/CT no more than 85 d apart was conducted...
December 21, 2023: Journal of Nuclear Medicine
#34
JOURNAL ARTICLE
Magdalena Mileva, Gwennaëlle Marin, Hugo Levillain, Carlos Artigas, Camille Van Bogaert, Clémentine Marin, Rachele Danieli, Amelie Deleporte, Simona Picchia, Konstantinos Stathopoulos, Christiane Jungels, Bruno Vanderlinden, Marianne Paesmans, Lieveke Ameye, Gabriela Critchi, Loubna Taraji-Schiltz, Chloe Velghe, Zéna Wimana, Maria Bali, Alain Hendlisz, Patrick Flamen, Ioannis Karfis
Our objective was to predict the outcome of peptide receptor radionuclide therapy (PRRT) using multimodality imaging and tumor dosimetry on gastroenteropancreatic neuroendocrine tumor (GEP-NET) lesions and patients. Methods: This prospective study included patients with progressive GEP-NETs. Treatment consisted of 4 cycles of 7.4 GBq of 177 Lu-DOTATATE. Imaging parameters were measured on 68 Ga-DOTATATE PET/CT (SUVmax/mean , somatostatin receptor [SSTR] tumor volume [TV], total lesion SSTR expression, and tumor-to-blood and tumor-to-spleen ratios), 18 F-FDG PET/CT (SUVmax/mean , metabolically active TV, and total lesion glycolysis), and diffusion-weighted MRI (apparent diffusion coefficient) in a maximum of 5 target lesions per patient at approximately 10 wk after each injection...
February 1, 2024: Journal of Nuclear Medicine
#35
REVIEW
Susan Richter, Charlotte Steenblock, Alessa Fischer, Sandy Lemm, Christian G Ziegler, Nicole Bechmann, Svenja Nölting, Jens Pietzsch, Martin Ullrich
Radionuclide therapies are an important tool for the management of patients with neuroendocrine neoplasms (NENs). Especially [131 I]MIBG and [177 Lu]Lu-DOTA-TATE are routinely used for the treatment of a subset of NENs, including pheochromocytomas, paragangliomas and gastroenteropancreatic tumors. Some patients suffering from other forms of NENs, such as medullary thyroid carcinoma or neuroblastoma, were shown to respond to radionuclide therapy; however, no general recommendations exist. Although [131 I]MIBG and [177 Lu]Lu-DOTA-TATE can delay disease progression and improve quality of life, complete remissions are achieved rarely...
2024: Theranostics
#36
JOURNAL ARTICLE
Yu Xing Zhao, Ou Wang, An Song, Lin Jie Wang, Feng Ying Gong, Lian Duan, Hong Bo Yang, Hui Pan, Hui Juan Zhu
OBJECTIVE: Summarize and analyze the characteristics of patients with Multiple Endocrine Neoplasia type 1 (MEN-1) who were diagnosed with malignant tumors that do not belong to MEN-1 components. METHODS: Clinical data from patients with MEN-1 who visited Peking Union Medical College Hospital between April 2012 and April 2022 were collected. We compared the clinical characteristics of patients with malignant tumors outside of their MEN-1 components to those without additional tumors...
December 31, 2023: Journal of Endocrinological Investigation
#37
REVIEW
Charles Marcus, Saima Muzahir, Rathan M Subramaniam
Significant improvement in molecular imaging and theranostics in the management of neuroendocrine tumors (NETs) has been made in the last few decades. Somatostatin receptor-targeted PET imaging outperforms conventional, planar, and single-photon emission computed tomography imaging and is indicated in the evaluation of these patients when available, resulting in a significant impact on staging, treatment response assessment, and restaging of these patients. Radionuclide therapy can have an impact on patient outcome in metastatic disease when not many treatment options are available...
December 30, 2023: PET Clinics
#38
JOURNAL ARTICLE
Kristen E Limbach, Kelly M Mahuron, Aaron T Scott, Philip H G Ituarte, Gagandeep Singh
Bone metastases from gastroenteropancreatic neuroendocrine neoplasms (GEPNENs) have been associated with poor prognosis, but it is unclear whether patients with concurrent bone metastases who receive liver-directed therapy (LDT) would derive survival benefit. The California Cancer Registry dataset, merged with data from the California Office of Statewide Health Planning and Development, was used to perform a retrospective study of GEPNENs metastatic to both liver and bone between 2000 and 2012. A total of 203 patients were identified...
December 13, 2023: Journal of Clinical Medicine
#39
JOURNAL ARTICLE
Julia Beck, Alexander Siebenhüner, Damian Wild, Emanuel Christ, Julie Refardt
The influence of sex on neuroendocrine neoplasms (NENs) has been scarcely investigated. Thus, this study aimed to compare tumor characteristics, treatment decisions, and overall survival in patients with NENs, stratified by sex. The retrospective analysis of the SwissNET cohort covered NENs of gastroenteropancreatic, pulmonary, or unknown origin from 07/14 - 09/22. The analysis included 1985 patients (46% female and 54% male). Male patients presented with higher staging at time of diagnosis and with more lymph node- and bone-metastases...
December 1, 2023: Endocrine-related Cancer
#40
JOURNAL ARTICLE
Tharani Krishnan, Maria Safro, Daniel Moreira Furlanetto, Sharlene Gill, Joao Paulo Solar Vasconcelos, Heather C Stuart, Patrick Martineau, Jonathan M Loree
Octreotide LAR is a long-acting somatostatin analogue (SSA) used in the management of metastatic gastroenteropancreatic neuroendocrine tumors (GEP NETs). It requires intramuscular (IM) injection. Missed IM injections cause subcutaneous nodules (SCNs) on radiologic images. We reviewed the rates of SCNs in a real-world cohort of GEP NETs receiving octreotide LAR and explored treatment outcomes. Patients commencing octreotide LAR between August 5, 2010 and March 8, 2018 at a single cancer center in Canada were identified from pharmacy records...
December 13, 2023: Journal of Neuroendocrinology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
